secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001628280-22-020614
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q2 revenue $103.4M (up 13% YoY); EPS $0.24; reiterates FY22 revenue guidance
--------------------------------------------------------------------------------

- Revenue $103.4M (Q2 2021: $91.6M); diluted EPS $0.24 vs $0.21.
- Reiterated FY2022 revenue guidance of $400-$430 million.
- Cash and investments $382.0 million, up $13.9 million from Q1 2022.
- Initiated Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
- Expects Phase 2 AIWG (miricorilant) and NASH data in Q4 2022; NDA submission for relacorilant in Cushing's in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828022020614/0001628280-22-020614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828022020614/cort-20220803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-020614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer